[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-511410-105":59,"doc-detail-511410-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","investing-in-the-development-conservation-of-new-antibiotic-treatments-dndis-engagement-origins-portfolio-and-partnerships","Investing in the Development & Conservation of New Antibiotic Treatments: DNDi’s Engagement - Origins, Portfolio, and Partnerships","","DNDi’s engagement focuses on addressing the lack of R&D for neglected diseases by creating and scaling a development pathway from research through translation, development, and implementation. The initiative highlights origins in 1999 and the establishment of founding partners, then emphasizes meeting immediate patient needs via new chemical entities, formulations, and new indications. A decade of R&D delivering six treatments is supported by criteria for success, extensive partnerships, regional clinical trial platforms, technology transfers, and measurable outcomes such as EUR 350+ million raised and large-scale screening capacity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/investing-in-the-development-conservation-of-new-antibiotic-treatments-dndis-engagement-origins-portfolio-and-partnerships/511410/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/investing-in-the-development-conservation-of-new-antibiotic-treatments-dndis-engagement-origins-portfolio-and-partnerships/511410.png","ImageObject",300,407,{"name":92,"@type":93},"asba","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-10-06",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the original motivation behind DNDi’s engagement in 1999?","Question",{"text":112,"@type":113},"The first meeting described the lack of R&D for neglected diseases, and MSF committed Nobel Peace Prize money to the DND Working Group.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does DNDi address immediate patient needs?",{"text":117,"@type":113},"It targets short- and long-term needs through new chemical entities, new formulations, and new indications for existing drugs, alongside completing registration dossiers.",{"name":119,"@type":110,"acceptedAnswer":120},"What kinds of partnerships and success criteria support DNDi’s work?",{"text":121,"@type":113},"DNDi relies on universities and research institutes, PDPs, international organizations and NGOs, CROs, and pharmaceutical companies, guided by shared vision, mutual understanding, and involvement throughout the full process.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},511410,1792200425,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},3985747872567,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Investing in the Development & Conservation of New Antibiotic Treatments: DNDi’s Engagement  \nOrigins of DNDi  \n1999  \n• First meeting to describe the lack of R&D for neglected diseases  \n• MSF commits the Nobel Peace Prize money to the DND Working Group  \n• JAMA article: ‘Access to essential drugs in poor countriesA Lost Battle?’  \nJuly 2003  \n• Creation of DNDi  \n• Founding partners:  \n• Institut Pasteur, France  \n• Indian Council of Medical Research, India  \n• Kenya Medical research Institute, Kenya  \n• Médecins Sans Frontières  \n• Ministry of Health, Malaysia  \n• Oswaldo Cruz Foundation/Fiocruz, Brazil  \n• WHO –TDR (Special Programme for Research and Training in Tropical Diseases) as a permanent  \nAMRoseI vrn, DNDi is ready for history to repeat itself based on what we have learned.  \nAddress Immediate Patient Needs & Deliver Innovative Medicines: Short-and Long-term  \nNew chemical entities (NCEs)  \nNew formulations  \nNew indications for existing drugs  \nCompleting registration dossier Geographical  \nResearch  \nTranslation  \nDevelopment  \nImplementation  \n> 5 3-5 1-2  \nyears  \nyears  \nyears  \nIn a decade of R&D, 6 new treatments delivered  \n􀀹 Easy to use  \n􀀹 Affordable  \n􀀹 Field-adapted  \n􀀹 Non-patented  \n• 30 projects, 6 diseases areas  \n• 15 entirely new chemical entities (NCEs)  \n• Over 130 partnerships, most in endemic countries  \n• 150 staff, half in endemic countries & 600 people working on DNDi projects  \n• Over EUR 350 million raised equally from public and private sources  \n• 3 regional disease-specific clinical trial platforms and 2 technology transfers  \nDNDi Portfolio: A mix of existing drugs & NCEs  \n6 new treatments delivered  \n15 NCEs   \n| Screen Hit to Lead Lead Opt. Pre-clinical Phase I Phase IIa/PoC Phase IIb/III Registration Access |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- |\n| HAT | \u003Cbr>SCYX1330682\u003Cbr>|  |  | \u003Cbr>SCYX-7158\u003Cbr>\u003Cbr>\u003Cbr>Fexinidazole\u003Cbr>|  |  | NECT |\n|  | \u003Cbr>SCYX1608210\u003Cbr>|  |  |  |  |  | Nifurtimox-Eflornithine Combination Therapy |\n| Leishmaniasis | \u003Cbr>Nitroimidazoles\u003Cbr>|  |  | \u003Cbr>Fexi sulfone\u003Cbr>\u003Cbr>\u003Cbr>Fexi/MF  combo |  |  | \u003Cbr>SSG&PM\u003Cbr>Africa |\n|  | S |  | \u003Cbr>Oxaleish\u003Cbr>| \u003Cbr>New treatments for HIV/VL |  |  | New VL\u003Cbr>Treatments |\n|  | C\u003Cbr>R |  | \u003Cbr>Amino pyrazoles\u003Cbr>| PKDL\u003Cbr>Asia/A |  |  | Asia |\n|  | E\u003Cbr>\u003Cbr>Leish H2L\u003Cbr>|  |  | frica |  |  |  |\n|  | E\u003Cbr>N |  |  | \u003Cbr>CpG-D35 (CL)\u003Cbr>\u003Cbr>\u003Cbr>Anfoleish (CL)\u003Cbr>\u003Cbr>\u003Cbr>New CL\u003Cbr>combos\u003Cbr>\u003Cbr>New VL\u003Cbr>Treatments\u003Cbr>Latin America |  |  |  |\n| Chagas | I\u003Cbr>N | \u003Cbr>Chagas H2L |  | \u003Cbr>New Benz  Regimens/ Combos |  |  | \u003Cbr>Benznidazole\u003Cbr>Paediatric Dosage Form |\n|  | G\u003Cbr>Biom |  |  | arkers |  | \u003Cbr>Fexinidazole\u003Cbr>|  |\n| Filaria | Macro Fil |  |  | \u003Cbr>aricide 2 | \u003Cbr>Emodepside\u003Cbr>|  |  |\n| Paediatric HIV |  |  |  | \u003Cbr>Two ‘4-in-1’ LPV/r based FDC granules\u003Cbr>LPV/r pellets NRTI FDC |  |  | with dual\u003Cbr> Malaria |\n|  |  |  |  | \u003Cbr>Superbooster HIV/TB |  |  |  |\n| Mycetoma |  |  |  | \u003Cbr>Fosravuconazole |  |  | \u003Cbr>ASAQ FDCArtesunate-Amodiaquine\u003Cbr>ASMQ FDCArtesunate-Mefloquine |\n\nDNDi’s success is only possible through innovative partnerships  \nUniversities & Research Institutes  \nPDPs  \nInt. Org.& NGOs  \nCROs  \nPharmaceutical companies  \nRESEARCH TRANSLATION DEVELOPMENT  \nIMPLEMENTATION  \nPLATFORM MEMBER COUNTRIES DNDi WORLDWIDE  \nFOUNDING PARTNERS  \nCRITERIA FOR SUCCESS  \n•Share the same vision  \n•Mutual understanding  \n•Involvement throughout the whole process  \nCombating malaria resistance: 2002 WHO recommendations  \nASAQ FDC: > 400 Million Treatments Distributed  \n• Pre-qualified by WHO in 2008  \n• \u003C1 USD for adults, \u003C 0.5 cents for children  \n• Easy-to-use, non-patented  \n• Registered: 30 African countries, India, Ecuador, Colombia  \n• First Risk Management Plan with MMV and Sanofi  \n• Transfer of technology to Zenufa (Tanzania)  \nIn partnership with Sanofi  \n120 ~~  ~~100 ~~  ~~80 ~~  ~~60 ~~  ~~40 ~~ ~~  \n20   \n0 ~~ ~~~~  ~~2007 2008 2009 2010 2011 2012 2013 2014  \n Other ASAQ FD","cbCaimVT1mkIeJ1t","https://ap.wps.com/l/cbCaimVT1mkIeJ1t","pdf",7634240,177,"English","# Origins of DNDi\n## Founding partners (1999)\n# Address immediate patient needs\n## New chemical entities, formulations, and indications\n# DNDi portfolio and development pathway\n## 6 new treatments delivered (including NCEs)\n# DNDi partnerships and success criteria\n## Research translation, implementation, and platform member countries\n# Case examples\n## Malaria resistance and ASAQ FDC\n## Large-volume drug screening capacity","[{\"question\":\"What was the original motivation behind DNDi’s engagement in 1999?\",\"answer\":\"The first meeting described the lack of R\\u0026D for neglected diseases, and MSF committed Nobel Peace Prize money to the DND Working Group.\"},{\"question\":\"How does DNDi address immediate patient needs?\",\"answer\":\"It targets short- and long-term needs through new chemical entities, new formulations, and new indications for existing drugs, alongside completing registration dossiers.\"},{\"question\":\"What kinds of partnerships and success criteria support DNDi’s work?\",\"answer\":\"DNDi relies on universities and research institutes, PDPs, international organizations and NGOs, CROs, and pharmaceutical companies, guided by shared vision, mutual understanding, and involvement throughout the full process.\"}]","Investing in the Development & Conservation of New Antibiotic Treatments: DNDi’s Engagement - Origins, Portfolio, and Partnerships | PDF",1791251629,446]